Drug Profile
Ibalizumab - TaiMed Biologics
Alternative Names: Hu1A8; Hu5A8; Ibalizumab-uiyk; TMB-355; TNX-355; TrogarzoLatest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator Biogen Idec
- Developer TaiMed Biologics; Theratechnologies
- Class Antiretrovirals; Monoclonal antibodies
- Mechanism of Action HIV fusion inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed HIV-1 infections
- Preclinical HIV-2 infections
Most Recent Events
- 18 Mar 2024 Ibalizumab Commercialized to AcedrA BioPharmaceuticals in the Middle East and North Africa Region
- 27 Feb 2024 Theratechnologies receives a refusal to file letter from the FDA for ibalizumab (Trogarzo®) in HIV-1 infections
- 02 Jan 2024 Preregistration for HIV-1 infections (Treatment-experienced) in USA (IM)